SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 30, 2019-- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in

-- Once-Daily, Orally Administered CCR4 Antagonist Blocks Recruitment of Th2 Inflammatory Immune Cells -- -- Potential to Treat Allergic Inflammatory Diseases Including Atopic Dermatitis -- SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--RAPT Therapeutics, Inc., a clinical-stage immunology-based

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company developing oral small molecules for oncology and inflammatory diseases, today announced the addition of Wendye Robbins, M.D., president and CEO of Blade Therapeutics,

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company developing oral small molecules for oncology and inflammatory diseases, today announced that Emma Guttman-Yassky, M.D., Ph.D., from the Department of Dermatology at

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company developing oral small molecules for oncology and inflammatory diseases, today announced the promotion of Dirk Brockstedt, Ph.D., to chief scientific officer and David

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company developing oral small molecules for oncology and inflammatory diseases, today announced that it secured an additional $37 million in an extension of its Series C

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--FLX Bio, a clinical-stage, immunology-based biopharmaceutical company, today announced it has changed its name to RAPT Therapeutics, Inc., to more accurately represent the company’s dedication and focused efforts to develop and commercialize oral

Cutting Edge Platform Enables the Detection of Changes in the Tumor Microenvironment Following Treatment with FLX475 MENLO PARK, Calif. & SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Personalis, Inc., a leader in advanced genomics for cancer, today announced that it has entered into a research

-- FLX193 Presents Potentially Attractive Alternative to Treatment with Injectable Biologics or Topical Corticosteroids -- SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--FLX Bio, Inc., a clinical-stage, immunology-focused biopharmaceutical company, today announced researchers presented preclinical

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target immune drivers of cancer and other immune-related disorders, today announced that Brian Wong, M.D., Ph.D., CEO will present